Literature DB >> 16616377

Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma.

Daudi K Langat1, J Sue Platt, Ossama Tawfik, Asgerally T Fazleabas, Joan S Hunt.   

Abstract

Human leukocyte antigen-G (HLA-G) is a major histocompatibility complex class Ib gene expressed in normal organs and in some tumors. The glycoproteins encoded by this gene are best known for their immunosuppressive properties. Because isoform-specific expression of HLA-G in male reproductive organs has not been reported, we investigated HLA-G1, -G2, -G5, -G6 mRNAs and proteins in four-to-five samples of normal prostate glands, prostates with benign prostatic hyperplasia and prostate adenocarcinomas using RT-PCR and immunohistochemistry. All tissues contained HLA-G1, -G2, -G5 and -G6 specific mRNAs, but only HLA-G5 protein was detectable. In normal prostate glands, HLA-G5 protein was prominent in the cytoplasm of tubuloglandular epithelia and in glandular secretions. Staining was reduced in samples of benign prostatic hyperplasia but remained localized to the cytoplasm of glandular epithelia and secretions. In prostatic adenocarcinomas, HLA-G5 protein was detectable mainly in the secretions. Thus, HLA-G5 but not HLA-G1, -G2 or -G6 is produced in the normal prostate and is present in prostatic secretions. In addition, normal cellular localization is disturbed in benign and malignant prostatic adenocarcinomas. The results are consistent with this molecule may influencing female immune receptivity to sperm and suggest that such immunosuppression could be disturbed in men with prostatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616377     DOI: 10.1016/j.jri.2006.01.006

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  9 in total

1.  A commentary on gestational programming and functions of HLA-G in pregnancy.

Authors:  J S Hunt; P J Morales; J L Pace; A T Fazleabas; D K Langat
Journal:  Placenta       Date:  2007-03-09       Impact factor: 3.481

Review 2.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

Review 3.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 4.  Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction.

Authors:  Line Lynge Nilsson; Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-05-13       Impact factor: 7.561

Review 5.  HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia.

Authors:  Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

6.  Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.

Authors:  Mohammad Hassan Heidari; Abolfazl Movafagh; Mohammad-Amin Abdollahifar; Shabnam Abdi; Mohamadreza Mashhoudi Barez; Hadi Azimi; Afshin Moradi; Amin Bagheri; Matineh Heidari; Jafar Hessam Mohseni; Maryam Tadayon; Hoda Mirsafian; Mahdi Ghatrehsamani
Journal:  Anat Cell Biol       Date:  2017-03-29

Review 7.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

Review 8.  The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy.

Authors:  Mette Dahl; Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  J Immunol Res       Date:  2014-03-04       Impact factor: 4.818

9.  Expression and potential roles of HLA-G in human spermatogenesis and early embryonic development.

Authors:  Gui-Dong Yao; Yi-Min Shu; Sen-Lin Shi; Zhao-Feng Peng; Wen-Yan Song; Hai-Xia Jin; Ying-Pu Sun
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.